BackgroundTimely treatment with neuraminidase inhibitors (NAI) can reduce severe outcomes in influenza patients.AimWe assessed the impact of antiviral treatment on in-hospital deaths of laboratory-confirmed influenza patients in 11 European Union countries from 2010/11 to 2019/20.MethodsCase-based surveillance data from hospitalised patients with known age, sex, outcome, ward, vaccination status, timing of antiviral treatment, and hospitalisation were obtained. A mixed effect logistic regression model using country as random intercept was applied to estimate the adjusted odds ratio (aOR) for in-hospital death in patients treated with NAIs vs not treated.ResultsOf 19,937 patients, 31% received NAIs within 48 hours of hospital admission. Older age (60-79 years aOR 3.0, 95% CI: 2.4-3.8; 80 years 8.3 (6.6-10.5)) and intensive care unit admission (3.8, 95% CI: 3.4-4.2) increased risk of dying, while early hospital admission after symptom onset decreased risk (aOR 0.91, 95% CI: 0.90-0.93). NAI treatment initiation within 48 hours and up to 7 days reduced risk of dying (0-48 hours aOR 0.51, 95% CI: 0.45-0.59; 3-4 days 0.59 (0.51-0.67); 5-7 days 0.64 (0.56-0.74)), in particular in patients 40 years and older (e.g. treatment within 48 hours: 40-59 years aOR 0.43, 95% CI: 0.28-0.66; 60-79 years 0.50 (0.39-0.63); ≥80 years 0.51 (0.42-0.63)).ConclusionNAI treatment given within 48 hours and possibly up to 7 days after symptom onset reduced risk of in-hospital death. NAI treatment should be considered in older patients to prevent severe outcomes.

Center for Virology Medical University Vienna Vienna Austria

Department of Infectious Diseases Epidemiology National Institute of Public Health Prague Czechia

European Centre for Disease Prevention and Control Stockholm Sweden

Health Service Executive Health Protection Surveillance Centre Dublin Ireland

Infectious Disease prevention and Control unit Malta

National Centre of Epidemiology CIBERESP Carlos 3 Health Institute Madrid Spain

National Influenza Reference Laboratory National Institute of Health Dr Ricardo Jorge Lisbon Portugal

National Institute for Public Health and the Environment Bilthoven the Netherlands

National Institute of Public Health Romania National Centre for Communicable Diseases Surveillance and Control Bucharest Romania

Public Health Agency of Sweden Stockholm Sweden

Sciensano Brussels Belgium

WHO Regional Office for Europe Copenhagen Denmark

Zobrazit více v PubMed

Nair H, Brooks WA, Katz M, Roca A, Berkley JA, Madhi SA, et al. Global burden of respiratory infections due to seasonal influenza in young children: a systematic review and meta-analysis. Lancet. 2011;378(9807):1917-30. . Available from: http://www.ncbi.nlm.nih.gov/pubmed/22078723 10.1016/S0140-6736(11)61051-9 PubMed DOI

Hayward AC, Fragaszy EB, Bermingham A, Wang L, Copas A, Edmunds WJ, et al. Comparative community burden and severity of seasonal and pandemic influenza: results of the Flu Watch cohort study. Lancet Respir Med. 2014;2(6):445-54. 10.1016/S2213-2600(14)70034-7 PubMed DOI PMC

World Health Organization (WHO). Global epidemiological surveillance standards for influenza. Geneva: WHO; 2013. [Accessed: 3 Jan 2023]. Available from: https://apps.who.int/iris/handle/10665/311261

Abraham GM, Morton JB, Saravolatz LD. Baloxavir: A Novel Antiviral Agent in the Treatment of Influenza. Clin Infect Dis. 2020;71(7):1790-4. 10.1093/cid/ciaa107 PubMed DOI

European Medicines Agency (EMA). Xofluza. Amsterdam: EMA. [Accessed: 3 Jan 2023]. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/xofluza

European Medicines Agency (EMA). Relenza. Amsterdam: EMA. [Accessed: 3 Jan 2023]. Available from: https://www.ema.europa.eu/en/relenza

European Medicines Agency (EMA). Tamiflu. Amsterdam: EMA. [Accessed: 3 Jan 2023]. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/tamiflu

European Medicines Agency (EMA). Influenza vaccines – quality module. Amsterdam: EMA. [Accessed: 3 Jan 2023]. Available from: https://www.ema.europa.eu/en/influenza-vaccines-quality-module

European medicines Agency (EMA). Update of EU recommendations for 2021-2022 seasonal flu vaccine composition. 2021. Amsterdam: EMA. [Accessed: 3 Jan 2023]. Available from: https://www.ema.europa.eu/en/news/update-eu-recommendations-2021-2022-seasonal-flu-vaccine-composition

Hayden FG, Asher J, Cowling BJ, Hurt AC, Ikematsu H, Kuhlbusch K, et al. Reducing influenza virus transmission: the value of antiviral treatment. Clin Infect Dis. 2022;74(3):532-40. 10.1093/cid/ciab625 PubMed DOI PMC

Domínguez A, Romero-Tamarit A, Soldevila N, Godoy P, Jané M, Martínez A, et al. Effectiveness of antiviral treatment in preventing death in severe hospitalised influenza cases over six seasons. Epidemiol Infect. 2018;146(7):799-808. 10.1017/S0950268818000663 PubMed DOI PMC

Duwe SC, Schmidt B, Gärtner BC, Timm J, Adams O, Fickenscher H, et al. Prophylaxis and treatment of influenza: options, antiviral susceptibility, and existing recommendations. GMS Infect Dis. 2021;9:Doc02. PubMed PMC

Muthuri SG, Myles PR, Venkatesan S, Leonardi-Bee J, Nguyen-Van-Tam JS. Impact of neuraminidase inhibitor treatment on outcomes of public health importance during the 2009-2010 influenza A(H1N1) pandemic: a systematic review and meta-analysis in hospitalized patients. J Infect Dis. 2013;207(4):553-63. 10.1093/infdis/jis726 PubMed DOI PMC

Liu JW, Lin SH, Wang LC, Chiu HY, Lee JA. Comparison of antiviral agents for seasonal influenza outcomes in healthy adults and children: a systematic review and network meta-analysis. JAMA Netw Open. 2021;4(8):e2119151. 10.1001/jamanetworkopen.2021.19151 PubMed DOI PMC

Hsu J, Santesso N, Mustafa R, Brozek J, Chen YL, Hopkins JP, et al. Antivirals for treatment of influenza: a systematic review and meta-analysis of observational studies. Ann Intern Med. 2012;156(7):512-24. 10.7326/0003-4819-156-7-201204030-00411 PubMed DOI PMC

Appiah GD, Chaves SS, Kirley PD, Miller L, Meek J, Anderson E, et al. Increased antiviral treatment among hospitalized children and adults with laboratory-confirmed influenza, 2010-2015. Clin Infect Dis. 2017;64(3):364-7. 10.1093/cid/ciw745 PubMed DOI PMC

Hooiveld M, van de Groep T, Verheij TJ, van der Sande MA, Verheij RA, Tacken MA, et al. Prescription of antiviral drugs during the 2009 influenza pandemic: an observational study using electronic medical files of general practitioners in the Netherlands. BMC Pharmacol Toxicol. 2013;14(1):55. 10.1186/2050-6511-14-55 PubMed DOI PMC

Doshi S, Kamimoto L, Finelli L, Perez A, Reingold A, Gershman K, et al. Description of antiviral treatment among adults hospitalized with influenza before and during the 2009 pandemic: United States, 2005-2009. J Infect Dis. 2011;204(12):1848-56. 10.1093/infdis/jir648 PubMed DOI

Snacken R, Brown C. New developments of influenza surveillance in Europe. Euro Surveill. 2015;20(4):21020. 10.2807/ese.20.04.21020-en PubMed DOI

Adlhoch C, Gomes Dias J, Bonmarin I, Hubert B, Larrauri A, Oliva Domínguez JA, et al. Determinants of fatal outcome in patients admitted to intensive care units with influenza, European Union 2009-2017. Open Forum Infect Dis. 2019;6(11):ofz462. . Available from: https://www.ncbi.nlm.nih.gov/pubmed/32258201 10.1093/ofid/ofz462 PubMed DOI PMC

European Centre for Disease Prevention and Control (ECDC). Seasonal influenza vaccination and antiviral use in EU/EEA Member States. Stockholm: ECDC, 2018. Available from: https://www.ecdc.europa.eu/en/publications-data/seasonal-influenza-vaccination-antiviral-use-eu-eea-member-states

Katzen J, Kohn R, Houk JL, Ison MG. Early oseltamivir after hospital admission is associated with shortened hospitalization: a 5-year analysis of oseltamivir timing and clinical outcomes. Clin Infect Dis. 2019;69(1):52-8. 10.1093/cid/ciy860 PubMed DOI

Campbell AP, Tokars JI, Reynolds S, Garg S, Kirley PD, Miller L, et al. Influenza antiviral treatment and length of stay. Pediatrics. 2021;148(4):e2021050417. 10.1542/peds.2021-050417 10.1542/peds.2021-050417 PubMed DOI

Louie JK, Yang S, Acosta M, Yen C, Samuel MC, Schechter R, et al. Treatment with neuraminidase inhibitors for critically ill patients with influenza A (H1N1)pdm09. Clin Infect Dis. 2012;55(9):1198-204. 10.1093/cid/cis636 PubMed DOI

Groeneveld GH, Marbus SD, Ismail N, de Vries JJC, Schneeberger P, Oosterheert JJ, et al. Effectiveness of oseltamivir in reduction of complications and 30-day mortality in severe seasonal influenza infection. Int J Antimicrob Agents. 2020;56(5):106155. 10.1016/j.ijantimicag.2020.106155 PubMed DOI

Myles P, Nguyen-Van-Tam JS, Semple MG, Brett SJ, Bannister B, Read RC, et al. Differences between asthmatics and nonasthmatics hospitalised with influenza A infection. Eur Respir J. 2013;41(4):824-31. 10.1183/09031936.00015512 PubMed DOI PMC

Olsen SJ, Winn AK, Budd AP, Prill MM, Steel J, Midgley CM, et al. Changes in influenza and other respiratory virus activity during the COVID-19 pandemic - United States, 2020-2021. MMWR Morb Mortal Wkly Rep. 2021;70(29):1013-9. 10.15585/mmwr.mm7029a1 PubMed DOI PMC

Adlhoch C, Mook P, Lamb F, Ferland L, Melidou A, Amato-Gauci AJ, et al. Very little influenza in the WHO European Region during the 2020/21 season, weeks 40 2020 to 8 2021. Euro Surveill. 2021;26(11):2100221. 10.2807/1560-7917.ES.2021.26.11.2100221 PubMed DOI PMC

Clark TW, Beard KR, Brendish NJ, Malachira AK, Mills S, Chan C, et al. Clinical impact of a routine, molecular, point-of-care, test-and-treat strategy for influenza in adults admitted to hospital (FluPOC): a multicentre, open-label, randomised controlled trial. Lancet Respir Med. 2021;9(4):419-29. 10.1016/S2213-2600(20)30469-0 PubMed DOI PMC

Brendish NJ, Malachira AK, Lillie PJ, Clark TW. Neuraminidase inhibitor use in adults presenting to hospital with suspected influenza: A questionnaire-based survey of practice among hospital physicians. Clin Infect Pract. 2021;11:100075. 10.1016/j.clinpr.2021.100075 DOI

Delgado-Sanz C, Mazagatos-Ateca C, Oliva J, Gherasim A, Larrauri A. Illness severity in hospitalized influenza patients by virus type and subtype, Spain, 2010-2017. Emerg Infect Dis. 2020;26(2):220-8. 10.3201/eid2602.181732 PubMed DOI PMC